vs
Element Solutions Inc（ESI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Element Solutions Inc的季度营收约是Revvity的1.1倍（$840.0M vs $772.1M），Revvity净利率更高（12.7% vs 6.7%，领先6.1%），Element Solutions Inc同比增速更快（41.0% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-74.2M），过去两年Element Solutions Inc的营收复合增速更高（17.1% vs 9.0%）
Element Solutions Inc是一家总部位于美国的特种化学品生产企业，专注于特种化学品领域的生产运营，于纽约证券交易所挂牌上市，业务覆盖全球多个市场，为各行业客户提供专业的特种化学品产品及相关解决方案。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ESI vs RVTY — 直观对比
营收规模更大
ESI
是对方的1.1倍
$772.1M
营收增速更快
ESI
高出35.1%
5.9%
净利率更高
RVTY
高出6.1%
6.7%
自由现金流更多
RVTY
多$236.0M
$-74.2M
两年增速更快
ESI
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $840.0M | $772.1M |
| 净利润 | $56.0M | $98.4M |
| 毛利率 | 38.4% | — |
| 营业利润率 | 13.3% | 14.5% |
| 净利率 | 6.7% | 12.7% |
| 营收同比 | 41.0% | 5.9% |
| 净利润同比 | -43.0% | 3.9% |
| 每股收益（稀释后） | $0.23 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESIRVTY
| Q1 26 | $840.0M | — | ||
| Q4 25 | $676.2M | $772.1M | ||
| Q3 25 | $656.1M | $698.9M | ||
| Q2 25 | $625.2M | $720.3M | ||
| Q1 25 | $593.7M | $664.8M | ||
| Q4 24 | $624.2M | $729.4M | ||
| Q3 24 | $645.0M | $684.0M | ||
| Q2 24 | $612.7M | $691.7M |
净利润ESIRVTY
| Q1 26 | $56.0M | — | ||
| Q4 25 | $6.2M | $98.4M | ||
| Q3 25 | $39.3M | $46.7M | ||
| Q2 25 | $47.4M | $53.9M | ||
| Q1 25 | $98.0M | $42.2M | ||
| Q4 24 | $54.7M | $94.6M | ||
| Q3 24 | $40.3M | $94.4M | ||
| Q2 24 | $93.2M | $55.4M |
毛利率ESIRVTY
| Q1 26 | 38.4% | — | ||
| Q4 25 | 40.9% | — | ||
| Q3 25 | 42.2% | 53.6% | ||
| Q2 25 | 42.6% | 54.5% | ||
| Q1 25 | 42.2% | 56.5% | ||
| Q4 24 | 41.0% | — | ||
| Q3 24 | 41.5% | 56.3% | ||
| Q2 24 | 43.6% | 55.7% |
营业利润率ESIRVTY
| Q1 26 | 13.3% | — | ||
| Q4 25 | 10.3% | 14.5% | ||
| Q3 25 | 15.4% | 11.7% | ||
| Q2 25 | 15.1% | 12.6% | ||
| Q1 25 | 13.0% | 10.9% | ||
| Q4 24 | 12.0% | 16.3% | ||
| Q3 24 | 14.7% | 14.3% | ||
| Q2 24 | 15.7% | 12.4% |
净利率ESIRVTY
| Q1 26 | 6.7% | — | ||
| Q4 25 | 0.9% | 12.7% | ||
| Q3 25 | 6.0% | 6.7% | ||
| Q2 25 | 7.6% | 7.5% | ||
| Q1 25 | 16.5% | 6.4% | ||
| Q4 24 | 8.8% | 13.0% | ||
| Q3 24 | 6.2% | 13.8% | ||
| Q2 24 | 15.2% | 8.0% |
每股收益（稀释后）ESIRVTY
| Q1 26 | $0.23 | — | ||
| Q4 25 | $0.03 | $0.86 | ||
| Q3 25 | $0.16 | $0.40 | ||
| Q2 25 | $0.20 | $0.46 | ||
| Q1 25 | $0.40 | $0.35 | ||
| Q4 24 | $0.22 | $0.77 | ||
| Q3 24 | $0.17 | $0.77 | ||
| Q2 24 | $0.39 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.3M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $5.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESIRVTY
| Q1 26 | $177.3M | — | ||
| Q4 25 | $626.5M | $919.9M | ||
| Q3 25 | $594.3M | $931.4M | ||
| Q2 25 | $529.9M | $991.8M | ||
| Q1 25 | $499.2M | $1.1B | ||
| Q4 24 | $359.4M | $1.2B | ||
| Q3 24 | $376.0M | $1.2B | ||
| Q2 24 | $309.3M | $2.0B |
总债务ESIRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — |
股东权益ESIRVTY
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.7B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.5B | $7.6B | ||
| Q4 24 | $2.4B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B |
总资产ESIRVTY
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.1B | $12.2B | ||
| Q3 25 | $5.0B | $12.1B | ||
| Q2 25 | $5.0B | $12.4B | ||
| Q1 25 | $4.8B | $12.4B | ||
| Q4 24 | $4.9B | $12.4B | ||
| Q3 24 | $5.1B | $12.8B | ||
| Q2 24 | $5.0B | $13.4B |
负债/权益比ESIRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.64× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.81× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-74.2M | $161.8M |
| 自由现金流率自由现金流/营收 | -8.8% | 21.0% |
| 资本支出强度资本支出/营收 | 3.0% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ESIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $182.0M | ||
| Q3 25 | $100.1M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | $26.0M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $98.5M | $147.9M | ||
| Q2 24 | — | $158.6M |
自由现金流ESIRVTY
| Q1 26 | $-74.2M | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | $83.6M | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | $15.0M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $85.9M | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率ESIRVTY
| Q1 26 | -8.8% | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | 12.7% | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | 2.5% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 13.3% | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度ESIRVTY
| Q1 26 | 3.0% | — | ||
| Q4 25 | 2.5% | 2.6% | ||
| Q3 25 | 2.5% | 2.6% | ||
| Q2 25 | 2.8% | 2.6% | ||
| Q1 25 | 1.9% | 2.4% | ||
| Q4 24 | 3.6% | 3.4% | ||
| Q3 24 | 2.0% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% |
现金转化率ESIRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.55× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 0.27× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.44× | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESI
| Electronics ex-Metals | $377.8M | 45% |
| Pass-through Metals | $255.7M | 30% |
| Other | $206.5M | 25% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
